Search

Your search keyword '"Hagemeister, Fredrick"' showing total 1,062 results
Start Over Author "Hagemeister, Fredrick"
1,062 results on '"Hagemeister, Fredrick"'

1. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial

Author

Gurumurthi, Ashwath, Chin, Collin K., Feng, Lei, Fowler, Nathan H., Strati, Paolo, Hagemeister, Fredrick B., Fayad, Luis E., Westin, Jason R., Obi, Chizobam, Arafat, Janine, Nair, Ranjit, Steiner, Raphael E., Neelapu, Sattva S., Flowers, Christopher R., and Nastoupil, Loretta J.

Published
2024
Full Text
View/download PDF

3. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, Park, Haeseong, Call, S Greg, Madwani, Kiran, Oki, Yasuhiro, Subbiah, Vivek, Hong, David S, Naing, Aung, Velez-Bravo, Vivianne M, Barnes, Tamara G, Hagemeister, Fredrick B, Falchook, Gerald S, Karp, Daniel D, Wheler, Jennifer J, Piha-Paul, Sarina A, Garrido-Laguna, Ignacio, Shpall, Elizabeth J, Fayad, Luis E, Neelapu, Sattva S, Meric-Bernstam, Funda, Kurzrock, Razelle, and Fanale, Michelle A

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Rare Diseases, Transplantation, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Everolimus, Female, Hematopoietic Stem Cell Transplantation, Histone Deacetylase Inhibitors, Histone Deacetylases, Hodgkin Disease, Humans, Male, Middle Aged, Recurrence, Sirolimus, Stem Cell Transplantation, TOR Serine-Threonine Kinases, Vorinostat, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePreclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma.Patients and methodsDuring the dose-escalation study (ClinicalTrials.gov number: NCT01087554) with the HDAC inhibitor vorinostat and the mTOR inhibitor sirolimus (V+S), a patient with Hodgkin lymphoma refractory to nine prior therapies demonstrated a partial response (PR) lasting for 18.5 months, which promoted additional enrollment of patients with Hodgkin lymphoma as well as exploration of an alternative combination of vorinostat and mTOR inhibitor everolimus (V+E).ResultsA total of 40 patients with refractory Hodgkin lymphoma received V+S (n = 22) or V+E (n = 18). Patients received a median of five prior therapies, including brentuximab (n = 39), autologous stem cell transplantation (n = 26), and allogeneic stem cell transplantation (n = 12). The most frequent grade ≥3 treatment-related adverse event was thrombocytopenia in 55% and 67% of patients treated with V+S and V+E, respectively. Complete response was reported in 6 (27%) patients treated with V+S and 2 (11%) patients treated with V+E, and PR was reported in 6 patients (27%) treated with V+S and 4 (22%) patients treated with V+E (objective response rate of 55% and 33%, respectively). In summary, combined HDAC and mTOR inhibition had encouraging activity in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma and warrants further investigation.ConclusionsCombined HDAC and mTOR inhibition has salutary activity in patients with relapsed refractory Hodgkin lymphoma and warrants further investigation.

Published
2020

4. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL

Author

Xu-Monette, Zijun Y, Zhang, Hongwei, Zhu, Feng, Tzankov, Alexandar, Bhagat, Govind, Visco, Carlo, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D, You, Hua, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés JM, Møller, Michael B, Parsons, Benjamin M, van Krieken, J Han, Piris, Miguel A, Winter, Jane N, Hagemeister, Fredrick B, Shahbaba, Babak, De Dios, Ivan, Zhang, Hong, Li, Yong, Xu, Bing, Albitar, Maher, and Young, Ken H

Subjects
Orphan Drug, Human Genome, Hematology, Cancer, Rare Diseases, Lymphoma, Biotechnology, Genetics, Generic health relevance, Good Health and Well Being, Artificial Intelligence, B-Lymphocytes, Germinal Center, High-Throughput Nucleotide Sequencing, Humans, Lymphoma, Large B-Cell, Diffuse
Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity of B-cell lymphoma. Cell-of-origin (COO) classification of DLBCL is required in routine practice by the World Health Organization classification for biological and therapeutic insights. Genetic subtypes uncovered recently are based on distinct genetic alterations in DLBCL, which are different from the COO subtypes defined by gene expression signatures of normal B cells retained in DLBCL. We hypothesize that classifiers incorporating both genome-wide gene-expression and pathogenetic variables can improve the therapeutic significance of DLBCL classification. To develop such refined classifiers, we performed targeted RNA sequencing (RNA-Seq) with a commercially available next-generation sequencing (NGS) platform in a large cohort of 418 DLBCLs. Genetic and transcriptional data obtained by RNA-Seq in a single run were explored by state-of-the-art artificial intelligence (AI) to develop a NGS-COO classifier for COO assignment and NGS survival models for clinical outcome prediction. The NGS-COO model built through applying AI in the training set was robust, showing high concordance with COO classification by either Affymetrix GeneChip microarray or the NanoString Lymph2Cx assay in 2 validation sets. Although the NGS-COO model was not trained for clinical outcome, the activated B-cell-like compared with the germinal-center B-cell-like subtype had significantly poorer survival. The NGS survival models stratified 30% high-risk patients in the validation set with poor survival as in the training set. These results demonstrate that targeted RNA-Seq coupled with AI deep learning techniques provides reproducible, efficient, and affordable assays for clinical application. The clinical grade assays and NGS models integrating both genetic and transcriptional factors developed in this study may eventually support precision medicine in DLBCL.

Published
2020

5. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Author

Cherng, Hua-Jay J., Alig, Stefan K., Oki, Yasuhiro, Nastoupil, Loretta J., Fayad, Luis, Neelapu, Sattva S., Turturro, Francesco, Hagemeister, Fredrick, Craig, Alexander F. M., Macaulay, Charles W., Rodriguez, Maria Alma, Lee, Hun Ju, McDonnell, Timothy J., Flowers, Christopher R., Vega, Francisco, Green, Michael R., Feng, Lei, Kurtz, David M., Alizadeh, Ash A., Davis, R. Eric, and Westin, Jason R.

Published
2023
Full Text
View/download PDF

6. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

Author

Saini, Neeraj Y, Saliba, Rima M, Rondon, Gabriela, Maadani, Farzaneh, Popat, Uday, Hosing, Chitra M, Oran, Betul, Bashir, Qaiser, Olson, Amanda, Nieto, Yago, Alousi, Amin, Kebriaei, Partow, Srour, Samer, Mehta, Rohtesh, Anderlini, Paolo, Shpall, Elizabeth J, Qazilbash, Muzaffar H, Khouri, Issa F, Fayad, Luis, Lee, Hun, Fowler, Nathan, Parmar, Simrit, Westin, Jason, Hagemeister, Fredrick, Champlin, Richard E, and Ciurea, Stefan O

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Immunology, Regenerative Medicine, Transplantation, Cancer, Orphan Drug, Hematology, Rare Diseases, Lymphoma, Good Health and Well Being, Adolescent, Adult, Aged, Allografts, Disease-Free Survival, Female, Graft vs Host Disease, Humans, Incidence, Male, Melphalan, Middle Aged, Retrospective Studies, Stem Cell Transplantation, Survival Rate, Tissue Donors, Vidarabine, Allogeneic transplantation, FM100 regimen, Haploidentical transplantation, Hodgkin lymphoma, Melphalan conditioning, Non-Hodgkin lymphoma, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

We analyzed 186 patients with lymphoma who underwent allogeneic stem cell transplantation (ASCT) with fludarabine-melphalan (FM) conditioning and different types of donors (25 haploidentical [HD], 98 matched unrelated [MUD], and 63 matched related [MRD]) at our institution between September 2009 and January 2018. Patients received fludarabine 160 mg/m2 (40 mg/m2/day for 4 days) in combination with 1 dose of melphalan 140 mg/m2 (FM140) or 100 mg/m2 (FM100). Engraftment was similar among the 3 groups (92%, 89%, and 98%, respectively; P = .7). The 6-month cumulative incidence of grade III-IV acute graft-versus-host disease (GVHD) was 4% in the HD group, 14% in the MUD group, and 8% in the MRD group (P not significant), and the respective 3-year cumulative incidence of chronic GVHD was 5%, 16%, and 26% (P not significant). The respective 3-year nonrelapse mortality and relapse rates were 31%, 32%, and 10% (HD versus MUD, P = .9; HD versus MRD, P = .02) and 15%, 21%, and 39% (HD versus MUD, P = .4; HD versus MRD, P = .04). At 3 years, progression-free survival (PFS) was 59%, 44%, and 46% (P not significant); overall survival (OS) was 52%, 54%, and 67% (P not significant); and GVHD-free, relapse-free survival was 39%, 31%, and 24% (P not significant). No differences in the 3-year PFS (57% versus 43%; P = .3) and OS (64% versus 58%; P = .7) were seen between patients receiving FM100 and those receiving FM140. Our data demonstrate that in patients with lymphoma, ASCT with HD transplants have similar outcomes as ASCT with HLA-matched transplants, and the FM100 conditioning regimen appears to be at least as effective as the FM140 regimen.

Published
2019

7. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Author

Cherng, Hua-Jay J., Sun, Ryan, Sugg, Bryant, Irwin, Russell, Yang, Haopeng, Le, Cao Cuong, Deng, Qing, Fayad, Luis, Fowler, Nathan H., Parmar, Simrit, Steiner, Raphael, Hagemeister, Fredrick, Nair, Ranjit, Lee, Hun Ju, Rodriguez, Maria, Samaniego, Felipe, Iyer, Swaminathan P., Flowers, Christopher R., Wang, Linghua, Nastoupil, Loretta J., Neelapu, Sattva S., Ahmed, Sairah, Strati, Paolo, Green, Michael R., and Westin, Jason

Published
2022
Full Text
View/download PDF

8. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Author

Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo

Published
2022
Full Text
View/download PDF

9. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

Author

Wang, Michael L, Jain, Preetesh, Zhao, Shuangtao, Lee, Hun Ju, Nastoupil, Loretta, Fayad, Luis, Ok, Chi Young, Kanagal-Shamanna, Rashmi, Hill, Holly A, Yao, Yixin, Hagemeister, Fredrick B, Westin, Jason R, Fowler, Nathan, Samaniego, Felipe, Steiner, Raphael, Nair, Ranjit, Iyer, Swaminathan P, Navsaria, Lucy, Badillo, Maria, Feng, Lei, Xuelin, Huang, Nogueras Gonzalez, Graciela M, Xu, Guofan, Wagner-Bartak, Nicolaus, Thirumurthi, Selvi, Santos, David, Tang, Guilin, Lin, Pei, Wang, Sa A, Jorgensen, Jeff, Yin, C Cameron, Li, Shaoying, Patel, Keyur P, Vega, Francisco, Medeiros, L Jeffery, Flowers, Christopher R, and Wang, Linghua

Published
2022
Full Text
View/download PDF

11. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Author

Albitar, Maher, Zhang, Hong, Goy, Andre, Xu-Monette, Zijun Y., Bhagat, Govind, Visco, Carlo, Tzankov, Alexandar, Fang, Xiaosheng, Zhu, Feng, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Hagemeister, Fredrick B., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Li, Yong, Xu, Bing, and Young, Ken H.

Published
2022
Full Text
View/download PDF

12. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, Nastoupil, Loretta J., Westin, Jason, Fayad, Luis E., Ahmed, Sairah, Fowler, Nathan H., Hagemeister, Fredrick B., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Adkins, Sherry, Claussen, Catherine M., Martinez, Charles S., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh E., Horowitz, Sandra, George, Shirley, Feng, Lei, Kebriaei, Partow, Shpall, Elizabeth J., Neelapu, Sattva S., Tummala, Sudhakar, and Chi, T. Linda

Published
2020
Full Text
View/download PDF

13. Can we cure refractory Hodgkin’s lymphoma with transplantation?

Author

Ciurea, Stefan O., Kongtim, Piyanuch, Srour, Samer, Saini, Neeraj, Im, Jin, Ramdial, Jeremy, Khouri, Issa, Anderlini, Paolo, Popat, Uday, Hosing, Chitra, Champlin, Richard E., Lee, Hun J., Fayad, Luis E., Hagemeister, Fredrick B., Bica, Ana M., Lipan, Lavinia, Craciun, Oana, Jercan, Cristina G., Tanase, Alina, and Colita, Anca

Published
2021
Full Text
View/download PDF

14. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Author

Gordon, Max J., primary, Feng, Lei, additional, Strati, Paolo, additional, Lee, Hun Ju, additional, Hagemeister, Fredrick B., additional, Westin, Jason R., additional, Samaniego, Felipe, additional, Marques‐Piubelli, Mario L., additional, Vega Vazquez, Francisco, additional, Parra Cuentas, Edwin R., additional, Solis‐Soto, Luisa M., additional, Ma, Wencai, additional, Wang, Jing, additional, Claret, Linda, additional, Averill, Barbara, additional, Ibanez, Karina, additional, Fayad, Luis E., additional, Flowers, Christopher R., additional, Green, Michael R., additional, Davis, R. Eric, additional, Neelapu, Sattva S., additional, Fowler, Nathan H., additional, and Nastoupil, Loretta J., additional

Published
2023
Full Text
View/download PDF

15. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Author

Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B, Fayad, Luis, Romaguera, Jorge E, Fowler, Nathan, Fanale, Michelle A, Kwak, Larry W, Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J, Wierda, William, Fu, Kai, Chan, Wing C, Vose, Julie M, O'Brien, Susan, Davis, Richard E, and Burger, Jan A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Rare Diseases, Lymphoma, Hematology, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Adenine, Antineoplastic Agents, B-Cell Activation Factor Receptor, Biomarkers, Tumor, Cell Line, Tumor, Chemokine CCL3, Chemokine CCL4, Enzyme-Linked Immunosorbent Assay, Epidemiologic Methods, Humans, Lymphoma, Large B-Cell, Diffuse, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Signal Transduction, chemokines, diffuse large B-cell lymphoma, lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

B cell receptor (BCR) signalling is an important pathway in diffuse large B cell lymphoma (DLBCL). In response to BCR triggering, normal and malignant B cells secrete the chemokines CCL3 and CCL4 to attract accessory cells to the tissue microenvironment. We measured CCL3 and CCL4 serum concentrations in 102 patients with newly diagnosed DLBCL by enzyme-linked immunosorbent assay, investigated their prognostic impact and validated our findings in an independent cohort of 51 patient samples. We also tested CCL3 and CCL4 secretion by DLBCL cells, and the influence of BTK inhibitors on the secretion of these chemokines. High CCL3 (≥40 pg/ml) serum concentrations correlated with higher international prognostic index, lactate dehydrogenase and β2 microglobulin, as did CCL4 (≥180 pg/ml) with advanced Ann Arbor stages. High CCL3 levels correlated with significantly shorter progression-free and overall survival. The in vitro studies demonstrated that activated B cell-like, but not germinal centre B cell-like DLBCL cells, secrete high levels of CCL3 and CCL4 after BCR triggering, which was exquisitely sensitive to BCR pathway inhibition. These findings support CCL3 and CCL4 protein concentrations as biomarkers for BCR pathway activation and prognosis in DLBCL.

Published
2015

17. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

Author

Saini, Neeraj Y., Saliba, Rima M., Rondon, Gabriela, Maadani, Farzaneh, Popat, Uday, Hosing, Chitra M., Oran, Betul, Bashir, Qaiser, Olson, Amanda, Nieto, Yago, Alousi, Amin, Kebriaei, Partow, Srour, Samer, Mehta, Rohtesh, Anderlini, Paolo, Shpall, Elizabeth J., Qazilbash, Muzaffar H., Khouri, Issa F., Fayad, Luis, Lee, Hun, Fowler, Nathan, Parmar, Simrit, Westin, Jason, Hagemeister, Fredrick, Champlin, Richard E., and Ciurea, Stefan O.

Published
2019
Full Text
View/download PDF

18. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Author

Gordon, Max J., Feng, Lei, Strati, Paolo, Lee, Hun Ju, Hagemeister, Fredrick B., Westin, Jason R., Samaniego, Felipe, Marques‐Piubelli, Mario L., Vega Vazquez, Francisco, Parra Cuentas, Edwin R., Solis‐Soto, Luisa M., Ma, Wencai, Wang, Jing, Claret, Linda, Averill, Barbara, Ibanez, Karina, Fayad, Luis E., Flowers, Christopher R., Green, Michael R., and Davis, R. Eric

Subjects
MUCOSA-associated lymphoid tissue lymphoma, LENALIDOMIDE, BRUTON tyrosine kinase, RITUXIMAB, FOLLICULAR lymphoma
Abstract

Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally designed, combination therapies with curative potential are needed. The immunomodulatory drug lenalidomide was evaluated in combination with rituximab for the frontline treatment of FL in the phase 3 RELEVANCE study. Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is active in NHL and was evaluated in combination with lenalidomide, rituximab, and ibrutinib (IRR) in a phase 1 study. Methods: The authors conducted an open‐label, phase 2 clinical trial of IRR for previously untreated FL and MZL. The primary end point was progression‐free survival (PFS) at 24 months. Results: This study included 48 participants with previously untreated FL grade 1–3a (N = 38), or MZL (N = 10). Participants received 12, 28‐day cycles of lenalidomide (15 mg, days 1–21 cycle 1; 20 mg, cycles 2–12), rituximab (375 mg/m2 weekly in cycle 1; day 1 cycles 2‐12), and ibrutinib 560 mg daily. With a median follow‐up of 65.3 months, the estimated PFS at 24 months was 78.8% (95% confidence interval [CI], 68.0%–91.4%) and 60‐month PFS was 59.7% (95% CI, 46.6%–76.4%). One death occurred unrelated to disease progression. Grade 3–4 adverse events were observed in 64.6%, including 50% with grade 3–4 rash. Conclusions: IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3–4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257). After 5 years of follow‐up from a phase 2 clinical trial of ibrutinib, lenalidomide, and rituximab in previously untreated patients with follicular and marginal zone lymphoma, the 5‐year progression‐free survival rate was 59.7% and the overall survival rate was 97.9%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL

Author

Xu-Monette, Zijun Y., primary, Li, Yong, additional, Snyder, Thomas, additional, Yu, Tiantian, additional, Lu, Tingxun, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Bhagat, Govind, additional, Qian, Wenbin, additional, Dybkaer, Karen, additional, Chiu, April, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Wang, Yingjun, additional, Go, Heounjeong, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Moller, Michael B., additional, Parsons, Benjamin M., additional, Fan, Xiangshan, additional, van Krieken, J.Han, additional, Piris, Miguel A., additional, Winter, Jane N., additional, Au, Qingyan, additional, Kirsch, Ilan, additional, Zhang, Mingzhi, additional, Shaughnessy, John, additional, Xu, Bing, additional, and Young, Ken H., additional

Published
2023
Full Text
View/download PDF

21. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

Author

Deng, Manman, Zhang, Mingzhi, Xu-Monette, Zijun Y., Pham, Lan V., Tzankov, Alexandar, Visco, Carlo, Fang, Xiaosheng, Bhagat, Govind, Zhu, Feng, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Choi, William W. L., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Hagemeister, Fredrick, Alinari, Lapo, Li, Yong, Andreeff, Michael, Xu, Bing, and Young, Ken H.

Published
2020
Full Text
View/download PDF

23. Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Data from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure from Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, primary, Marques-Piubelli, Mario L., primary, Dai, Enyu, primary, Dang, Minghao, primary, Ma, Man Chun John, primary, Li, Xubin, primary, Yang, Haopeng, primary, Henderson, Jared, primary, Kudryashova, Olga, primary, Meerson, Mark, primary, Isaev, Sergey, primary, Kotlov, Nikita, primary, Nomie, Krystle J., primary, Bagaev, Alexander, primary, Parra, Edwin R., primary, Solis Soto, Luisa M., primary, Parmar, Simrit, primary, Hagemeister, Fredrick B., primary, Ahmed, Sairah, primary, Iyer, Swaminathan P., primary, Samaniego, Felipe, primary, Steiner, Raphael, primary, Fayad, Luis, primary, Lee, Hun, primary, Fowler, Nathan H., primary, Flowers, Christopher R., primary, Strati, Paolo, primary, Westin, Jason R., primary, Neelapu, Sattva S., primary, Nastoupil, Loretta J., primary, Vega, Francisco, primary, Wang, Linghua, primary, and Green, Michael R., primary

Published
2023
Full Text
View/download PDF

26. Data from Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

Author

Deng, Manman, primary, Xu-Monette, Zijun Y., primary, Pham, Lan V., primary, Wang, Xudong, primary, Tzankov, Alexandar, primary, Fang, Xiaosheng, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, You, Hua, primary, Huh, Jooryung, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, Hagemeister, Fredrick, primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Liu, Phillip, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Tables 1-5 and Supplementary Figures 1-8 from Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

Author

Deng, Manman, primary, Xu-Monette, Zijun Y., primary, Pham, Lan V., primary, Wang, Xudong, primary, Tzankov, Alexandar, primary, Fang, Xiaosheng, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, You, Hua, primary, Huh, Jooryung, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, Hagemeister, Fredrick, primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Liu, Phillip, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

28. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential

Author

Li, Yong, primary, Xu-Monette, Zijun Y., additional, Abramson, Jeremy, additional, Sohani, Aliyah R., additional, Bhagat, Govind, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Zhang, Shanxiang, additional, Dybkaer, Karen, additional, Pan, Zenggang, additional, Xu, Min, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Go, Heounjeong, additional, van Krieken, J. Han, additional, Winter, Jane N., additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J. M., additional, Møller, Michael B., additional, Piris, Miguel A., additional, Wang, Yingjun, additional, Zhang, Mingzhi, additional, and Young, Ken H., additional

Published
2023
Full Text
View/download PDF

29. Supplementary Figure from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Wei, Li, primary, Fang, Xiaosheng, primary, Au, Qingyan, primary, Nunns, Harry, primary, Nagy, Máté, primary, Tzankov, Alexandar, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, Hagemeister, Fredrick B., primary, Sun, Xiaoping, primary, Han, Xin, primary, Go, Heounjeong, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Albitar, Maher, primary, You, Hua, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

30. Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Data from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Wei, Li, primary, Fang, Xiaosheng, primary, Au, Qingyan, primary, Nunns, Harry, primary, Nagy, Máté, primary, Tzankov, Alexandar, primary, Zhu, Feng, primary, Visco, Carlo, primary, Bhagat, Govind, primary, Dybkaer, Karen, primary, Chiu, April, primary, Tam, Wayne, primary, Zu, Youli, primary, Hsi, Eric D., primary, Hagemeister, Fredrick B., primary, Sun, Xiaoping, primary, Han, Xin, primary, Go, Heounjeong, primary, Ponzoni, Maurilio, primary, Ferreri, Andrés J.M., primary, Møller, Michael B., primary, Parsons, Benjamin M., primary, van Krieken, J. Han, primary, Piris, Miguel A., primary, Winter, Jane N., primary, Li, Yong, primary, Xu, Bing, primary, Albitar, Maher, primary, You, Hua, primary, and Young, Ken H., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 6 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

33. Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

36. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Author

Westin, Jason, primary, Davis, R. Eric, additional, Feng, Lei, additional, Hagemeister, Fredrick, additional, Steiner, Raphael, additional, Lee, Hun Ju, additional, Fayad, Luis, additional, Nastoupil, Loretta, additional, Ahmed, Sairah, additional, Rodriguez, Alma, additional, Fanale, Michelle, additional, Samaniego, Felipe, additional, Iyer, Swaminathan P., additional, Nair, Ranjit, additional, Oki, Yasuhiro, additional, Fowler, Nathan, additional, Wang, Michael, additional, Ma, Man Chun John, additional, Vega, Francisco, additional, McDonnell, Timothy, additional, Pinnix, Chelsea, additional, Griffith, Donna, additional, Lu, Yang, additional, Tewari, Sanjit, additional, Sun, Ryan, additional, Scott, David W., additional, Flowers, Christopher R., additional, Neelapu, Sattva, additional, and Green, Michael R., additional

Published
2023
Full Text
View/download PDF

37. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

Author

Pinnix, Chelsea C., Shah, Jatin J., Chuang, Hubert, Costelloe, Colleen M., Medeiros, L. Jeffrey, Wogan, Christine F., Reed, Valerie, Smith, Grace L., Milgrom, Sarah, Patel, Krina, Huo, Jinhai, Turturro, Francesco, Romaguera, Jorge, Fayad, Luis, Oki, Yasuhiro, Fanale, Michelle A., Westin, Jason, Nastoupil, Loretta, Hagemeister, Fredrick B., Rodriguez, Alma, Qazilbash, Muzaffar, Shah, Nina, Bashir, Qaiser, Ahmed, Sairah, Nieto, Yago, Hosing, Chitra, Rohren, Eric, and Dabaja, Bouthaina

Published
2016
Full Text
View/download PDF

39. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma

Author

Pinnix, Chelsea C., Smith, Grace L., Milgrom, Sarah, Osborne, Eleanor M., Reddy, Jay P., Akhtari, Mani, Reed, Valerie, Arzu, Isidora, Allen, Pamela K., Wogan, Christine F., Fanale, Michele A., Oki, Yasuhiro, Turturro, Francesco, Romaguera, Jorge, Fayad, Luis, Fowler, Nathan, Westin, Jason, Nastoupil, Loretta, Hagemeister, Fredrick B., Rodriguez, M. Alma, Ahmed, Sairah, Nieto, Yago, and Dabaja, Bouthaina

Published
2015
Full Text
View/download PDF

40. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial

Author

Oki, Yasuhiro, Ewer, Michael S., Lenihan, Daniel J., Fisch, Michael J., Hagemeister, Fredrick B., Fanale, Michelle, Romaguera, Jorge, Pro, Barbara, Fowler, Nathan, Younes, Anas, Astrow, Alan B., Huang, Xuelin, Kwak, Larry W., Samaniego, Felipe, McLaughlin, Peter, Neelapu, Sattva S., Wang, Michael, Fayad, Luis E., Durand, Jean-Bernard, and Alma Rodriguez, M.

Published
2015
Full Text
View/download PDF

41. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL

Author

Nair, Ranjit, primary, Ayers, Amy, additional, Nastoupil, Loretta J., additional, Gunther, Jillian R., additional, Fayad, Luis, additional, Fowler, Nathan H., additional, Miranda, Roberto N., additional, Hagemeister, Fredrick B., additional, Lee, Hun Ju, additional, Rodriguez, Maria Alma, additional, Steiner, Raphael, additional, Strati, Paolo, additional, Nieto, Yago, additional, Ramdial, Jeremy L., additional, Chihara, Dai, additional, Wang, Michael L., additional, Malpica Castillo, Luis E, additional, Saini, Neeraj, additional, Jain, Preetesh, additional, Pinnix, Chelsea C., additional, Dabaja, Bouthaina S., additional, Green, Michael R, additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Marques-Piubelli, Mario L., additional, Vega, Francisco, additional, Noorani, Mansoor, additional, Ahmed, Sairah, additional, Westin, Jason, additional, Neelapu, Sattva S., additional, Feng, Lei, additional, and Iyer, Swaminathan Padmanabhan, additional

Published
2022
Full Text
View/download PDF

42. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Author

Li, Xubin, primary, Deng, Qing, additional, Henderson, Jared, additional, Watson, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Fayad, Luis, additional, Iyer, Swaminathan Padmanabhan, additional, Hagemeister, Fredrick B., additional, Nastoupil, Loretta J., additional, Fowler, Nathan H., additional, Westin, Jason, additional, Steiner, Raphael, additional, Nair, Ranjit, additional, Ahmed, Sairah, additional, Alatrash, Gheath, additional, Neelapu, Sattva S., additional, Strati, Paolo, additional, and Green, Michael R, additional

Published
2022
Full Text
View/download PDF

43. Additional file 1 of PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma

Author

Steiner, Raphael E., Parra, Edwin R., Vega, Francisco, Feng, Lei, Westin, Jason R., Neelapu, Sattva S., Strati, Paolo, Green, Michael R., Flowers, Christopher R., Solis, Luisa M., Wistuba, Ignacio I., Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B., Noorani, Mansoor, and Marques-Piubelli, Mario L.

Abstract

Additional file 1: Methods; Figure S1. Representative pictures showing different cell densities of CD30+PD-L1+ cells. A-C) Multiplex immunofluorescence image of a case with low cell density of CD30+, PD-L1+, and CD30+PD-L1+ cells median: 20.46 cells/mm2, respectively. D-E) Multiplex immunofluorescence image of a case with high cell density of CD30+, PD-L1+, and CD30+PD-L1+ cells (median: 604.62 cells/mm2), respectively. Supplementary Table 1.

Published
2023
Full Text
View/download PDF

44. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Author

Fowler, Nathan H, Davis, R Eric, Rawal, Seema, Nastoupil, Loretta, Hagemeister, Fredrick B, McLaughlin, Peter, Kwak, Larry W, Romaguera, Jorge E, Fanale, Michelle A, Fayad, Luis E, Westin, Jason R, Shah, Jatin, Orlowski, Robert Z, Wang, Michael, Turturro, Francesco, Oki, Yasuhiro, Claret, Linda C, Feng, Lei, Baladandayuthapani, Veerabhadran, Muzzafar, Tariq, Tsai, Kenneth Y, Samaniego, Felipe, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

45. Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant

Author

Cherng, Hua‐Jay J., primary, Xu, Guofan, additional, Feng, Lei, additional, Steiner, Raphael, additional, Fayad, Luis, additional, Strati, Paolo, additional, Nair, Ranjit, additional, Nastoupil, Loretta J., additional, Lee, Hun Ju, additional, Neelapu, Sattva S., additional, Flowers, Christopher R., additional, Rodriguez, Maria, additional, Wang, Michael, additional, Hagemeister, Fredrick, additional, Pinnix, Chelsea C., additional, Ramdial, Jeremy, additional, Srour, Samer, additional, Nieto, Yago, additional, Rezvani, Katayoun, additional, Champlin, Richard, additional, Kebriaei, Partow, additional, Westin, Jason, additional, Macapinlac, Homer A., additional, Shpall, Elizabeth, additional, and Ahmed, Sairah, additional

Published
2022
Full Text
View/download PDF

47. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation

Author

Dabaja, Bouthaina S., Hess, Kenneth, Shihadeh, Ferial, Podoloff, Donald A., Medeiros, L. Jeffrey, Mawlawi, Osama, Arzu, Isidora, Oki, Yasuhiro, Hagemeister, Fredrick B., Fayad, Luis E., Reed, Valerie K., Kedir, Aziza, Wogan, Christine F., and Rodriguez, Alma

Published
2014
Full Text
View/download PDF

48. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Author

Westin, Jason R, Chu, Fuliang, Zhang, Min, Fayad, Luis E, Kwak, Larry W, Fowler, Nathan, Romaguera, Jorge, Hagemeister, Fredrick, Fanale, Michelle, Samaniego, Felipe, Feng, Lei, Baladandayuthapani, Veerabhadran, Wang, Zhiqiang, Ma, Wencai, Gao, Yanli, Wallace, Michael, Vence, Luis M, Radvanyi, Laszlo, Muzzafar, Tariq, Rotem-Yehudar, Rinat, Davis, R Eric, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

49. Pre‐treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma

Author

Reddy, Jay P., Hernandez, Mike, Gunther, Jillian R., Dabaja, Bouthaina S., Martin, Geoffrey V., Jiang, Wen, Akhtari, Mani, Allen, Pamela K., Atkinson, Bradley J., Smith, Grace L., Pinnix, Chelsea C., Milgrom, Sarah A., Abou Yehia, Zeinab, Osborne, Eleanor M., Oki, Yasuhiro, Lee, Hun, Hagemeister, Fredrick, and Fanale, Michelle A.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results